Document Detail


Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
MedLine Citation:
PMID:  21528780     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS AND BACKGROUND: We investigated the efficacy of docetaxel plus prednisone in Italian patients with metastatic hormone-refractory prostate cancer (mHRPC).
METHODS: Twenty four patients with mHRPC received docetaxel 75 mg/m2 every 3 weeks plus prednisone 5 mg twice daily for up to six cycles. The primary endpoint was efficacy measured by a reduction in serum prostate specific antigen (PSA) levels and measurable disease. Evaluation of toxicity, quality of life and reduction of pain were secondary endpoints.
RESULTS: PSA response was seen in 18 patients (75%). We observed a partial response in 2 patients (8.3%), stable disease in 10 patients (41.7%), and disease progression in 12 patients (50%). Severe neutropenia was reported in 12.5% of patients.
CONCLUSIONS: Treatment with docetaxel every three weeks is an effective and well tolerated therapeutic option in patients with mHRPC.
Authors:
G Cicero; R De Luca
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  15     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-05-02     Completed Date:  2011-06-07     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  325-31     Citation Subset:  IM    
Affiliation:
Oncology Department, Medical Oncology Unit, Policlinico Universitario, University of Palermo, Italy. giuseppecicero@unipa.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / blood,  drug therapy*,  secondary
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Disease Progression
Drug Resistance, Neoplasm*
Humans
Italy
Male
Middle Aged
Neoplasm Staging
Prednisone / administration & dosage
Prostate-Specific Antigen / blood
Prostatic Neoplasms / blood,  drug therapy*,  pathology
Taxoids / administration & dosage
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Taxoids; 15H5577CQD/docetaxel; 53-03-2/Prednisone; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exophiala oligosperma involved in a refractory chronic rhinosinusitis.
Next Document:  A preliminary study of the local treatment of preneoplastic and malignant skin lesions using methyl ...